News

Ranbaxy said that it plans to manufacture the zolpidem tartrate tablets in 5mg and 10mg strengths. The products will be manufactured at the company’s New Jersey Ohm Laboratories

The deal will see UK-based GW receive milestone payments of up to $273 million, including a signature fee of $18 million from Otsuka. In addition, Otsuka will bear

Sales increased 11.6% to GBP1.5 billion, driven by the expansion of healthcare services and an increased demand for medical electrical products. Lloydspharmacy increased its services for Primary Care

The launch of the erythropoiesis-stimulating agent, which increases the production of red blood cells, coincides with an FDA warning on the drug class. The US drug regulator recently

SCOLR Pharma said it planned to continue the development of a 12-hour extended release ibuprofen product and would either seek to work with another large pharmaceutical company or

The phase III TeloVac trial has been designed by the Pancreatic Cancer Clinical Sub-Group of the UK National Cancer Research Institute and will be run by Cancer Research

The decision was based on five, company-sponsored pediatric studies conducted at the request of the FDA, according to J&J. The extension gives the company marketing exclusivity on Levaquin

Medicare announced a national coverage analysis on the use of erythropoiesis stimulating agents (ESAs) for the conditions other than end-stage renal disease, the first step toward issuing a

The company, which specializes in the prevention and treatment of infectious diseases, has filed a notice of appeal at the Civilian Board of Contract Appeals regarding the contract